Purespring secures $105m to start Phase I/II trial of IgAN gene therapy
Purespring Therapeutics has raised $105m in a Series B funding round which will help progress its lead candidate PS-002 to clinic.
Purespring Therapeutics has raised $105m in a Series B funding round which will help progress its lead candidate PS-002 to clinic.
What's Your Reaction?
